CLGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CollPlant Biotechnologies Ltd (CLGN) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock exhibits bearish technical indicators, lacks strong positive momentum, and has financial challenges despite revenue growth. The recent downgrade by an analyst and concerns over financing further dampen its appeal. It is better to hold off on investing until clearer positive trends emerge.
The technical indicators for CLGN are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 20.108, and moving averages show a bearish pattern (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 0.637, with key support levels at 0.559 and 0.51, and resistance levels at 0.715 and 0.763.
CollPlant recently launched the BioFlex bioink kit for DLP 3D bioprinting, which could advance drug discovery and tissue engineering. This innovation may attract attention in the biotech sector.
The company announced a $2M registered direct financing, which raised investor concerns and led to a downgrade by an analyst. Additionally, the company faces significant financial challenges, including a net income drop of -19.49% YoY and a gross margin decline of -96.28% YoY.
In Q3 2025, revenue increased significantly by 1825.00% YoY to $77,000. However, net income dropped to -$3,483,000 (-19.49% YoY), EPS fell to -0.27 (-28.95% YoY), and gross margin declined sharply to -249.35 (-96.28% YoY).
On 2026-02-06, D. Boral Capital analyst Jason Kolbert downgraded CLGN to Hold from Buy, citing concerns over the company's recent $2M financing and its disproportionate impact on investor sentiment.
